company background image
CORT

Corcept Therapeutics NasdaqCM:CORT Stock Report

Last Price

US$25.64

Market Cap

US$2.7b

7D

2.2%

1Y

29.2%

Updated

30 Sep, 2022

Data

Company Financials +
CORT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance6/6
Financial Health6/6
Dividends0/6

CORT Stock Overview

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States.

Corcept Therapeutics Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Corcept Therapeutics
Historical stock prices
Current Share PriceUS$25.64
52 Week HighUS$29.93
52 Week LowUS$15.83
Beta0.56
1 Month Change-0.70%
3 Month Change0.79%
1 Year Change29.23%
3 Year Change80.69%
5 Year Change25.87%
Change since IPO109.65%

Recent News & Updates

Sep 27
Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Sep 23

Corcept extends distribution agreement for Cushing’s syndrome drug

Corcept Therapeutics Incorporated (NASDAQ:CORT), the maker of Cushing’s syndrome medication Korlym, has extended its partnership with specialty pharmacy Optime Care, Inc., for U.S. distribution of the treatment. As part of the Sep. 16 amendment to the pharmaceutical manufacturer services agreement, Optime will continue to serve as the exclusive specialty pharmacy dispensing Korlym in the U.S. until Mar. 31, 2024, CORT said in a regulatory filing. In 2017, CORT and Optime entered into a distribution services agreement for the U.S. sales of Korlym, a once-daily oral therapy indicated to treat hyperglycemia secondary to hypercortisolism in certain adults with Cushing’s syndrome. “Korlym is delivering steady sales and earning growth,” and the company is advancing its pipeline with a strong balance sheet, Seeking Alpha contributor Bret Jensen wrote in a recent article on CORT.

Sep 06

Corcept Therapeutics: A Status Check

Summary Today, we put the spotlight on Corcept Therapeutics for the first time in more than a year. The company's Korlym is delivering steady sales and earning growth, the company has a solid balance sheet, and Corcept Therapeutics is also advancing its pipeline. An investment analysis follows in the paragraphs below.

Shareholder Returns

CORTUS PharmaceuticalsUS Market
7D2.2%-0.04%-2.5%
1Y29.2%3.2%-23.2%

Return vs Industry: CORT exceeded the US Pharmaceuticals industry which returned 5.2% over the past year.

Return vs Market: CORT exceeded the US Market which returned -21.5% over the past year.

Price Volatility

Is CORT's price volatile compared to industry and market?
CORT volatility
CORT Average Weekly Movement5.1%
Pharmaceuticals Industry Average Movement11.2%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: CORT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: CORT's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998238Joseph Belanoffhttps://www.corcept.com

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess.

Corcept Therapeutics Incorporated Fundamentals Summary

How do Corcept Therapeutics's earnings and revenue compare to its market cap?
CORT fundamental statistics
Market CapUS$2.75b
Earnings (TTM)US$112.72m
Revenue (TTM)US$392.03m

24.4x

P/E Ratio

7.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CORT income statement (TTM)
RevenueUS$392.03m
Cost of RevenueUS$5.20m
Gross ProfitUS$386.83m
Other ExpensesUS$274.11m
EarningsUS$112.72m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.05
Gross Margin98.67%
Net Profit Margin28.75%
Debt/Equity Ratio0%

How did CORT perform over the long term?

See historical performance and comparison